Metformin
- Generic Name
- Metformin
- Brand Names
- Actoplus Met, Avandamet, Fortamet, Glucophage, Glucovance, Glumetza, Glycon, Invokamet, Janumet, Jentadueto, Kazano, Kombiglyze, Komboglyze, Qternmet, Riomet, Segluromet, Synjardy, Trijardy, Velmetia, Xigduo
- Drug Type
- Small Molecule
- Chemical Formula
- C4H11N5
- CAS Number
- 657-24-9
- Unique Ingredient Identifier
- 9100L32L2N
- Background
Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.
Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "insulin sensitizer", leading to a decrease in insulin resistance and a clinically significant reduction of plasma fasting insulin levels. Another well-known benefit of this drug is modest weight loss, making it an effective choice for obese patients type II diabetes.
Metformin was first approved in Canada in 1972, and received subsequent FDA approval in the US in 1995.
- Indication
Metformin immediate-release formulations
Metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years old with type 2 diabetes mellitus.
Metformin extended-release tablet (XR)
The extended-release formulation of metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Safety in children has not been determined to this date.
Metformin combination products
Metformin is a component of a variety of combination products with other anti-diabetic agents. It is indicated, along with diet and exercise, to improve glycemic control in adult patients with type 2 diabetes mellitus in combination with DPP-4 inhibitors (sitagliptin, linagliptin, alogliptin, or saxagliptin), in combination with SGLT2 inhibitors (canagliflozin, empagliflozin, ertugliflozin, or dapagliflozin), or in combination with pioglitazone.
- Associated Conditions
- Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Polycystic Ovarian Syndrome (PCOS), Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate
- Associated Therapies
- -
A Study to Explore Pharmacokinetic Interaction Between Rilpivirine and Metformin in Healthy Participants
- First Posted Date
- 2012-11-01
- Last Posted Date
- 2014-03-06
- Lead Sponsor
- Janssen R&D Ireland
- Target Recruit Count
- 20
- Registration Number
- NCT01719614
Effectiveness of Metformin in Recurrent Miscarriage in a Woman With Hyperinsulinaemia
- First Posted Date
- 2012-10-31
- Last Posted Date
- 2021-01-08
- Lead Sponsor
- Woman's Health University Hospital, Egypt
- Registration Number
- NCT01718340
- Locations
- 🇪🇬
Women's Health Hospital, Assiut, Egypt
A Pilot Study to Assess the Glucose Lowering Effect of Metformin and Sitagliptin in Adolescents With Type 1 Diabetes
- Conditions
- Type 1 Diabetes
- Interventions
- First Posted Date
- 2012-10-31
- Last Posted Date
- 2017-04-24
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 21
- Registration Number
- NCT01718093
- Locations
- 🇺🇸
Baylor College of Medicine, Houston, Texas, United States
ß-Cell Function and Glycemic Control in Newly Diagnosed Type 2 Diabetic Patients With Moderate Hyperglycemia
- First Posted Date
- 2012-10-31
- Last Posted Date
- 2012-10-31
- Lead Sponsor
- Taipei Veterans General Hospital, Taiwan
- Target Recruit Count
- 160
- Registration Number
- NCT01717911
- Locations
- 🇨🇳
Taipei Veterans General Hospital, Taipei, Taiwan
A Study to Assess the Safety and Efficacy of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control (MK-3102-011)
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2012-10-30
- Last Posted Date
- 2018-09-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 329
- Registration Number
- NCT01717313
Metformin as a Chemoprevention Agent in Non-small Cell Lung Cancer
- Conditions
- Carcinoma, Non-Small-Cell LungLung Neoplasms
- Interventions
- Other: Placebo ComparatorDrug: Metformin
- First Posted Date
- 2012-10-30
- Last Posted Date
- 2020-03-10
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 6
- Registration Number
- NCT01717482
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
A Study of the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose When Added to Sitagliptin + Metformin Combination Therapy in Chinese Participants With Diabetes (MK-0431-313)
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2012-10-18
- Last Posted Date
- 2018-08-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 5570
- Registration Number
- NCT01709305
Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin (MK-3102-022)
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2012-10-11
- Last Posted Date
- 2018-09-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 307
- Registration Number
- NCT01704261
A Study to Assess the Safety and Tolerability of Sitagliptin/Simvastatin Fixed-dose Combination (FDC) in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-312)
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2012-10-08
- Last Posted Date
- 2018-08-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 42
- Registration Number
- NCT01702298
An Endometrial Cancer Chemoprevention Study of Metformin
- Conditions
- Gynecology
- Interventions
- Other: PlaceboDrug: MetforminProcedure: Endometrial BiopsyBehavioral: Lifestyle InterventionBehavioral: Questionnaires
- First Posted Date
- 2012-10-02
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 100
- Registration Number
- NCT01697566
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.